---
title: "ALM: Net sales up 7.5% YoY to €602.7M, driven by dermatology and biologics growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293703263.md"
description: "Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.Original document: Almirall SA [ALM] Slides Release — Jul. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-24T05:02:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293703263.md)
  - [en](https://longbridge.com/en/news/293703263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293703263.md)
generator: "portal-rs"
---

# ALM: Net sales up 7.5% YoY to €602.7M, driven by dermatology and biologics growth

Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.

Original document: Almirall SA \[ALM\] Slides Release — Jul. 24 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ALM.US](https://longbridge.com/en/quote/ALM.US.md)
- [MCO.US](https://longbridge.com/en/quote/MCO.US.md)

## Related News & Research

- [Almonty launches share buyback of up to US$300 million, 14,400,000 shares](https://longbridge.com/en/news/296098060.md)
- [BUZZ-Tungsten miner Almonty climbs on $300 mln stock buyback](https://longbridge.com/en/news/296113349.md)
- [HCL: Strong H2 rebound, XTclave™ launch, and robust pipelines position both divisions for FY27 growth](https://longbridge.com/en/news/296840662.md)
- [Kerry Properties: Revenue fell sharply but profit and margins improved; long-term outlook remains positive](https://longbridge.com/en/news/296798348.md)
- [TLV: Strong H1 2026 profit growth and capital strength amid macroeconomic challenges](https://longbridge.com/en/news/296790736.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**